Pharma giants tout AI tools as high priority in half-year earnings reports

Big Phar­ma com­pa­nies are catch­ing the ar­ti­fi­cial in­tel­li­gence wave, ev­i­denced by a num­ber of drug­mak­ers’ com­ments in their half-year earn­ings re­ports this week.

A hand­ful of com­pa­nies high­light­ed their AI ef­forts across drug de­vel­op­ment, man­u­fac­tur­ing and com­mer­cial­iza­tion, in­clud­ing As­traZeneca, Roche, Take­da and GSK so far. Con­sult­ing firm McK­in­sey & Com­pa­ny re­port­ed a “rapid rise” in phar­ma part­ner­ships with AI com­pa­nies back in Oc­to­ber, iden­ti­fy­ing near­ly 270 com­pa­nies in the AI-dri­ven drug dis­cov­ery space.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN